

**ASX RELEASE**

**22nd April 2021**

### **SHAREHOLDER UPDATE AND PRESENTATION**

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new drugs for the treatment of cancer and fibrosis, is pleased to announce that at **10:30am on Wednesday 28 April, 2021** Amplia’s CEO and Managing Director, Dr John Lambert will host a shareholder update webinar. The online presentation will follow release of the Company’s Appendix 4C and Quarterly Update.

Interested parties are requested to register for the update using this link: (<https://bit.ly/3n3knN0>)

Registrants will receive a confirmation email containing information about joining the webinar.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

#### **For Further Information**

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).